These diseases are often metastasizing cancers like multiple myeloma, breast cancer and prostate cancer aragonching et al. Hormone therapy was given instead of zoledronic acid. One of the serious adverse effects of bisphosphonate therapy is bisphosphonaterelated osteonecrosis of the jaw bronj. Efficacy of a highdose antiresorptive drug holiday to. The american college of prosthodontists agrees with the recommendation for the term, medicationrelated osteonecrosis of the jaw mronj suggested by the american association of maxillofacial surgeons aaoms to replace the previous, morespecific term, bisphosphonaterelated. Bisphosphonaterelated osteonecrosis of the jaw bone. Mri evaluation of bisphosphonaterelated osteonecrosis of the jaw. Review article bisphosphonaterelated osteonecrosis of the jaw. Bps antiresorptive activity substantially reduce fracture risk by 40%70% in osteoporosis patients, and improve quality of life in cancer patients by preventing skeletal complications. Osteonecrosis of the jaw onj is a serious side effect of bisphosphonate use in patients with osteoporosis, pagets disease, hypercalcemia of malignancy, metastatic bone disease and multiple myeloma, although recently this complication has also been reported in patients under non. The american association of oral and maxillofacial surgeons aaoms considers as vitally important that information on bronj be disseminated to other dental and medical specialties.
The american association of oral and maxillofacial surgeons aaoms considers as vitally important that information on bronj be disseminated to. Evidence has emerged that bisphosphonate use in cancer patients is associated with osteonecrosis of the jaw. Bisphosphonate related osteonecrosis of the jaw 2009 canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw medical practitioners who prescribe bisphosphonate therapies should be aware and ensure their patients are aware of the potential risk of bisphosphonate related. Bisphosphonaterelated osteonecrosis of the jaw in patients with osteoporosis. Bisphosphonate related osteonecrosis of the jaw bronj is a serious oral complication of bisphosphonate treatment involving the exposure of necrotic maxillary or mandibular bone. Medication related osteonecrosis of the jaw mronj, which was first described in 2002, is a relatively uncommon but potentially serious side effect of treatment with osteoclast inhibitors, such as intravenous highpotency bisphosphonates and denosumab, which decrease the risk of skeletal related events in patients with cancer and metastatic bone disease. However, the postmarketing experience with intravenous and, to a much lesser extent, oral bisphosphonates has raised concerns about potential side effects related to profound bone remodeling inhibition and osteonecrosis isolated to the jaws. Bisphosphonate related osteonecrosis of the jaw bronj is a postsurgical lesion, in which bone exposure in the maxillofacial region persists for more than 8 weeks, in patients undergoing or underwent bisphosphonate treatment and without history of. Pdf bisphosphonaterelated osteonecrosis of the jaw bronj is a dramatic disintegration of the jaw that affects patients treated with. Bisphosphonate complications including osteonecrosis of the jaw. Clinical study bisphosphonate related osteonecrosis of the jaw. This is an update to the previous sdcep oral health management of patients. Bisphosphonate related osteonecrosis of the jaw jiacd.
Bisphosphonaterelated osteonecrosis of the jaw is defined as an exposure of necrotic bone in maxillofacial region, which persists more than 8 weeks in patients treated or, in course of. An update on bisphosphonaterelated osteonecrosis of the jaw. Review article bisphosphonaterelated osteonecrosis of. Bisphosphonate osteonecrosis bisphosphonates and osteonecrosis of the jaw bisphosphonate medications are linked to a risk of osteonecrosis of the jaw. Position statement of the american college of prosthodontists pdf link. Medication related osteonecrosis of the jaw mon, mronj is progressive death of the jawbone in a person exposed to a medications known to increase the risk of disease, in the absence of a previous radiation treatment. Oral bisphosphonate related osteonecrosis of jaws bronj. After the first case of mronj reported by marx in 2003 1 as bisphosphonate related necrosis, there has been a continual emergence of novel medications, which have also been implicated in osteonecrosis of the jaw onj. The efficacy of these drugs is due to their ability to inhibit osteoclastmediated bone resorption. Osteonecrosis of the jaw and bisphosphonates in cancer. American association of oral and maxillofacial surgeons position paper on bisphosphonate related osteonecrosis of the jaw 2009 update. Objective bisphosphonate related osteonecrosis of the jaw bronj is a rare but serious side effect of bisphosphonates bps.
Bionj is commonly precipitated by a tooth extraction in patients treated with long term, potent, high dose intravenous bisphosphonates for the management of. Bronj is a severe, challenging condition, characterized by exposure, pain, infection of necrotic bone, with masticatory and speech problems. Although this complication has also been reported in patients receiving antiresorptive agents for. Bisphosphonaterelated osteonecrosis of the jaw and dental. Bisphosphonateassociated osteonecrosis of the jaw is an important condition seen most commonly in oncology patients receiving highdose intravenous bisphosphonates. Medication related osteonecrosis of the jaw mronj is a rare, severe debilitating condition from unknown causes. The underlying etiology is unclear and may be multifactorial. Diagnostic tissue sampling may exacerbate the process and is.
Bisphosphonaterelated osteonecrosis of the jaw rsna. Bisphosphonate related osteonecrosis of the jaw bronj can adversely affect quality of life, as it may produce significant morbidity. The purpose of this study was to present a large series of cases of this association. For patients with malignant disease taking bisphosphonates and denosumab, the incidence of medication related osteonecrosis of the jaw mronj is up to 15% in contrast to 0. Bronj is associated with pain, paresthesia, and oral dysfunction generating an impairment of the quality of life.
Medication related osteonecrosis of the jaw mronj was first reported in 2002 and has become an increasingly recognised problem in patients receiving bisphosphonates and denosumab for bony malignancies. Lowdose bisphosphonates given either orally or intravenously in osteoporosis patients have not been causally linked to the development of osteonecrosis of the jaw. It is a serious, albeit rare adverse reaction affecting jaw bones through an unknown mechanism, with potential to cause catastrophic tissue destruction 18. Medicationrelated osteonecrosis of the jaw wikipedia. With the increased use of bisphosphonates in the treatment of osteoporosis and other conditions as multiple myeloma and bone metastasis and their complications hypercalcemia, pain, pathologic fractures, nephrotoxicity, electrolyte abnormalities, and spinal cord compression, a side effect difficult to manage was observed. Further, tooth extraction and infection have been overwhelmingly linked to bronj ikebe, 20. The following protocols have been developed by the bc cancer agency department of oral oncology. It may lead to surgical complication in the form of impaired wound healing following oral and maxillofacial surgery, periodontal surgery, or endodontic therapy. How cancer patients can lower the risk of bisphosphonate. Bisphosphonaterelated osteonecrosis of the jaw and its.
Bisphosphonaterelated osteonecrosis of the jaw complicated. In the last two decades, there has been a rapid increase in the incidence of medication related osteonecrosis of the jaw mronj. Bisphosphonate related osteonecrosis of the jaw an update. This article covers the authors experience with the treatment of bisphosphonaterelated osteonecrosis of the jaw in 11 individuals. This study tested hyperbaric oxygen hbo as an adjunct to surgery and antibiotics in the treatment of bisphosphonate related osteonecrosis of the jaw onj and evaluated its effects on gingival healing, pain, and quality of life. Strategies for management of patients with or at risk for bronj were set forth in the american association of oral and maxillofacial. Oral bisphosphonate related osteonecrosis of the jaw. Medicationrelated osteonecrosis of the jaw unrelated to. Although generally well tolerated, a rare but potentially severe side effect is the bisphosphonate related osteonecrosis of the jaw bronj, an entity first described in 2003.
Clinical study bisphosphonate related osteonecrosis of the. Prevention of osteonecrosis of the jaw onj in patients. The special committee favors the term medication related osteonecrosis of the jaw mronj. Histomorphologic characteristics of bisphosphonate. Ruggiero, dmd, md,a john fantasia, dds,b and eric carlson, dmd, mdc, new hyde park, ny, and knoxville, tn. In view of the widespread use of chronic bisphosphonate therapy, the observation of an associated risk of osteonecrosis of the jaw should alert practitioners to monitor for this previously unrecognized complication and to reevaluate the indications for and the duration of bisphosphonate therapy in patients with osteopeniaosteoporosis and cancer. Prevention of medicationrelated osteonecrosis of the jaw. Since this disease has no independent code in either of the diseases or in the medical procedures classifications, it is hard to estimate how many bp patients are affected. Bisphosphonates related osteonecrosis of the jaw bronj is related to the development of avascular osteonecrosis or osteochemonecrosis 1, 2. Bisphosphonate related osteonecrosis of the jaw bronj is a welldocumented devastating side effect of longterm bisphosphonate bp use.
Bisphosphonate associated osteonecrosis of the jaw is an important condition seen most commonly in oncology patients receiving highdose intravenous bisphosphonates. Bisphosphonate associated osteonecrosis of the jaw. In 2003, bisphosphonaterelated osteonecrosis of the jaw bronj was first reported, with the demonstration of 36 bone lesions of the mandible andor maxilla in. Since 2003 an increasing number of bisphosphonate related osteonecrosis of the jaw bronj were reported. From the molecular viewpoint, bps are postulated to modulate the function of osteoclasts, reacting with a surface. Oral bisphosphonates are the most commonly prescribed antiresorptive drugs for the treatment of osteoporosis. Bisphosphonaterelated osteonecrosis of the jaw onj is characterized by nonhealing exposed bone in the maxillofacial region in patients who. Database analysis of the risk factors of bisphosphonate. Pdf bisphosphonate related osteonecrosis of the jaw. Bisphosphonate related osteonecrosis of the jaw onj is characterized by nonhealing exposed bone in the maxillofacial region in patients who have undergone bisphosphonate treatment. Bisphosphonate and medicationrelated osteonecrosis of the.
Bisphosphonaterelated osteonecrosis of the jaw broj was first described in north american literature in 2003. No specific pathologic aspects or histological features are included in the most current definition. Oral health management of patients at risk of medication. Bisphosphonates related osteonecrosis of the jaw bronj is a pathological condition characterized by bone exposure or latent infection in patients treated with the drug. Any invasive procedures for patients taking bisphosphonates increase risk of osteonecrosis of the jaw 3, 4. Accumulating recent reports describe that surgical dental treatments in patients with cancer or osteoporosis who have been receiving intravenous or oral bps are associated with osteonecrosis of the jaw bisphosphonaterelated osteonecrosis of the jaw, bronj.
Bisphosphonate related osteonecrosis of the jaw bone. Bisphosphonates bps are effective drugs widely used to treat osteoporosis, pagets disease, osteogenesis imperfecta and skeletal complications induced by metastatic cancer. The american college of prosthodontists agrees with the recommendation for the term, medication related osteonecrosis of the jaw mronj suggested by the american association of maxillofacial surgeons aaoms to replace the previous, morespecific term, bisphosphonate. Objective bisphosphonaterelated osteonecrosis of the jaw bronj is a rare but serious side effect of bisphosphonates bps. Aftimos 1 nationalinstituteofpathology,facultyofmedicine,lebaneseuniversity,rac hariricampus,baabda. Oral health management of patients at risk of medication related osteonecrosis of the jaw has been developed to help dental practitioners to manage the routine dental treatment of patients prescribed drugs associated with medication related osteonecrosis of the jaw mronj.
James olutayo 1,2, jimoh olubanwo agbaje 3, reinhilde jacobs 1, vicky verhaeghe 3, filip vande velde 4, frans vinckier 3. Bisphosphonate related osteonecrosis of the jaw is now well documented in the literature and has been subject to several prescribing safety alerts from the medicines and healthcare products regulatory agency and the european medicines agency. It is often denoted as bisphosphonate related osteonecrosis of the jaw bronj. The canadian task force on osteonecrosis of the jaw, with representatives from medical, surgical, and pathology disciplines, has developed canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. Radiological pattern and the potential role of cbct in early diagnosis. Aug 09, 20 bisphosphonates related osteonecrosis of the jaw bronj is related to the development of avascular osteonecrosis or osteochemonecrosis 1, 2. Jan 01, 2006 bisphosphonate therapy has been incorporated in the standard management of patients with multiple myelomarelated bony disease. Journal of the chinese medical association 78 2015 76e79.
In 2002, the food and drug administration fda received first reports related to several patients with cancer, treated with the iv bisphosphonates bp, who developed osteonecrosis of the jaw. A retrospective study of patients diagnosed and treated for bisphosphonaterelated osteonecrosis of the jaw at the department of dentistry, university hospital hradec kralove during the period january. Importance of microcracks in etiology of bisphosphonate related osteonecrosis of the jaw. The change is justified to accommodate the growing number of osteonecrosis cases involving the maxilla and mandible associated with other antiresorptive denosumab. Although their efficacy in reducing skeletal related events is important in the supportive management of the myeloma patient, postmarketing experience with this class of agents, particularly the more potent intravenous agents pamidronate and zoledronic acid, have. Bisphosphonate related osteonecrosis of the jaw bronj adversely affects the quality of life, producing significant morbidity in afflicted patients.
Pdf bisphosphonaterelated osteonecrosis of the jaw. The american college of prosthodontists agrees with the recommendation for the term, medication related osteonecrosis of the jaw mronj suggested by the american association of maxillofacial surgeons aaoms to replace the previous, morespecific term, bisphosphonate related. However, there are several adverse effects associated with oral bisphosphonates including the bisphosphonate related osteonecrosis of the jaw bronj. However, the involvement of stromal cells, especially fibroblasts, in the oral cavity is unclear. Osteonecrosis of the jaws onj, also called antiresorptive agentinduced osteonecrosis of the jaw aronj and medication related osteonecrosis of the jaw, is an oral complication in patients receiving bisphosphonate or rankl inhibitor therapy.
Pdf bisphosphonate related osteonecrosis of the jaw an. Calcium phosphate ceramics can prevent bisphosphonate. Bisphosphonates and osteonecrosis of the jaw bisphosphonate medications are linked to a risk of osteonecrosis of the jaw. Endodontic implications of bisphosphonateassociated. Medication related osteonecrosis of the jaw guidance for the oncology multidisciplinary team 6 mronj in the adjuvant setting the frequency of mronj from oral bisphosphonates in the early breast cancer setting is 0. Bionj is commonly precipitated by a tooth extraction in patients treated with long term, potent, high dose intravenous bisphosphonates for the management of myeloma, breast or prostate. Jomr bisphosphonaterelated osteonecrosis of the jaw bone. Page 3 medicationrelated osteonecrosis of the jaw 2014 update commonly misdiagnosed conditions may include, but position paper are not limited to.
The special committee recommends changing the nomenclature of bisphosphonaterelated osteonecrosis of the jaw bronj. Medicationrelated osteonecrosis of the jaw2014 update. American association of oral and maxillofacial surgeons. A diagnosis of bisphosphonate associated osteonecrosis of the jaw relies on three criteria. Treatment for bisphosphonaterelated osteonecrosis of the jaw. A typical presentation includes some combination of a painful, nonhealing. Bisphosphonaterelated osteonecrosis of the jaws bronj presents the clinician with significant management dilemmas. Osteonecrosis of the jaw in patients treated with bisphosphonates is a relatively rare but well known complication at maxillofacial units around the world. Bisphosphonate related osteonecrosis of the jaw bronj is a dramatic disintegration of the jaw that affects patients treated with bisphosphonates bps for diseases characterized by bone loss.
Prevention of bisphosphonaterelated osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acida prospective study over 6 years. Bisphosphonaterelated osteonecrosis of the jaw scielo. Review article bisphosphonaterelated osteonecrosis of the. However, prolonged bp use is associated with a significant dental complication termed bisphosphonaterelated osteonecrosis of the jaw bronj. Medicationrelated osteonecrosis the authors 2020 of the. It has been speculated that the medication, especially longterm i. One of the serious adverse effects of bisphosphonate therapy is bisphosphonate related osteonecrosis of the jaw bronj.
Bisphosphonaterelated osteonecrosis of the jaw bronj a new complication of interest to the dental profession has been recently referred to as bronj. This form of osteonecrosis has been termed bisphosphonate induced osteonecrosis of the jaw bionj. Bisphosphonate related osteonecrosis of the jaws rev bras reumatol 2011. This describes a spectrum of intraoral symptoms, especially seen in cancer patients treated with high levels of intravenous bisphosphonates. Bisphosphonaterelated osteonecrosis of the jaw in patients with. Medication related osteonecrosis of the jaw mronj is a pathologic process that rarely follows exposure to antiresoptive agents such as bisphosphonate or denosumab, which are used to treat lytic bone lesions in patients with osseous metastases related to carcinoma of the breast or prostate, multiple myeloma, pagets disease, and osteoporo.
A study of 18 cases associated with fungal infection v. There is scarce information in the literature on bronj associated with dental implants dis. Since this disease has no independent code in either of the diseases or in the medical procedures classifications, it is. It is characterized by nonhealing exposed bone in a patient with a history of antiresorptive or antiangiogenic agents in the absence of radiation exposure to the head and neck region. Bisphosphonate complications including osteonecrosis of. Although oral bisphosphonates remain the most commonly implicated prescribed agents, several other. To address the current situation of bronj in japan, the allied task force committee of bisphosphonaterelated osteonecrosis of the jaw. Bisphosphonaterelated osteonecrosis of the jaw associated. Bisphosphonate related osteonecrosis of the jaw rev bras reumatol 2012. Bisphosphonaterelated osteonecrosis of the jaw, revisited.
Bisphosphonate related osteonecrosis of the jaw bronj is defined as the exposure of the bone in the maxillofacial region more than 8 weeks in patients who are under bisphosphonate treatment without any radiation treatment, and who. Osteonecrosis of the jaw an overview sciencedirect topics. Bisphosphonaterelated osteonecrosis of the jaw bronj is a condition defined by the presence of exposed mandibular or maxillary bone that does not heal within 8 weeks in a patient exposed to bisphosphonates who has not received radiation therapy directed to the jaws. Experience with the treatment of bisphosphonaterelated. Pdf what is the role of hyperbaric oxygen in the management.
1615 374 694 909 958 58 1373 670 1493 457 1269 569 726 583 1147 248 1213 210 1512 989 241 654 795 239 268 368 357 1158 256